GlassScriptPhysician profile
Katia Rayburn
NPI 1740870583
$1,945.08
in general payments reported to CMS, 2019-2025
23 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.80 · 2022: $478 · 2023: $392 · 2024: $569 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $447.09 | 2022-2025 | |
| Gilead Sciences, INC. | $227.73 | 2021-2022 | |
| Pfizer INC. | $185.66 | 2023-2024 | |
| Janssen Biotech, INC. | $161.11 | 2022-2025 | Tremfya |
| Novo Nordisk INC | $142.88 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Endo Pharmaceuticals INC. | $125.94 | 2022 | |
| Viiv Healthcare Company | $104.07 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $66.90 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $65.12 | 2025 | Tremfya, Stelara |
| Lilly USA, LLC | $53.46 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Shield Therapeutics INC | $50.58 | 2023-2024 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $47.92 | 2023-2024 | Farxiga, Airsupra |
| Acadia Pharmaceuticals INC | $36.93 | 2024 | Nuplazid |
| Exact Sciences Corporation | $30.56 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.53 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $25.06 | 2024 | Veozah |
| Aimmune Therapeutics, INC. | $23.79 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.64 | 2023 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $21.91 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $21.46 | 2023 | Spravato |
| Theratechnologies INC. | $20.35 | 2022 | |
| Boston Scientific Corporation | $18.57 | 2022 | |
| Esperion Therapeutics, INC. | $15.82 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katia Rayburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.